Status:
WITHDRAWN
Role of Intralipid in Management of Organophosphorus Poisoning
Lead Sponsor:
Amani Hassan Abdel-Wahab
Conditions:
Organophosphorus Poisoning
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
PHASE3
Brief Summary
Aim of the study: To assess the role of intralipid emulsion in the acute man-agement of organophosphorus toxicity and its benefits in de-creasing mortality rates among victims.
Detailed Description
Organophosphates (OPs) are cholinesterase inhibitors that are widely used as pesticides and organophosphate (OP) poisoning is an important public health concern in Egypt especially in the rural farmin...
Eligibility Criteria
Inclusion
- Age group of 18-60 years who are exposed to organophosphorus compounds.
- Clinical manifestations of organophosphorus toxidromes (hyper-salivation, lacrimation, sweating, urinary incontinence, di-arrhea, vomiting and abdominal pain).
Exclusion
- Patient or relative in charge refusal.
- Chronic renal or liver disease manifested by history, clinical and investigatory diagnosis.
- Previous history of acute or chronic pancreatitis
- Combined poisoning with non OP compounds
- Asymptomatic patients.
- Contraindications to intralipid emulsion as:
- disturbances of normal fat metabolism such as patho-logic hyperlipemia manifested by history, clinical and investigatory diagnosis.
- lipoid nephrosis manifested by history, clinical and investigatory diagnosis.
Key Trial Info
Start Date :
April 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2025
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04393103
Start Date
April 1 2024
End Date
January 1 2025
Last Update
October 3 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.